| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria, Falciparum | 74 | 2025 | 219 | 15.890 |
Why?
|
| Plasmodium falciparum | 75 | 2025 | 245 | 13.800 |
Why?
|
| Antimalarials | 40 | 2025 | 124 | 8.730 |
Why?
|
| Drug Resistance | 40 | 2025 | 152 | 7.570 |
Why?
|
| Burkitt Lymphoma | 16 | 2025 | 73 | 5.440 |
Why?
|
| Malaria | 27 | 2025 | 148 | 5.340 |
Why?
|
| Artemisinins | 18 | 2025 | 38 | 5.300 |
Why?
|
| Protozoan Proteins | 32 | 2025 | 126 | 5.140 |
Why?
|
| Military Medicine | 22 | 2022 | 33 | 4.860 |
Why?
|
| Epstein-Barr Virus Infections | 11 | 2025 | 103 | 4.810 |
Why?
|
| Herpesvirus 4, Human | 14 | 2025 | 196 | 3.700 |
Why?
|
| High-Throughput Nucleotide Sequencing | 23 | 2025 | 313 | 3.290 |
Why?
|
| Mutation | 20 | 2025 | 2612 | 2.910 |
Why?
|
| Antigens, Protozoan | 10 | 2024 | 56 | 2.060 |
Why?
|
| Military Personnel | 12 | 2022 | 120 | 1.560 |
Why?
|
| Humans | 155 | 2025 | 63443 | 1.470 |
Why?
|
| Malaria Vaccines | 5 | 2023 | 37 | 1.450 |
Why?
|
| Whole Genome Sequencing | 6 | 2025 | 81 | 1.380 |
Why?
|
| Genetic Variation | 15 | 2025 | 383 | 1.360 |
Why?
|
| Selection, Genetic | 7 | 2025 | 83 | 1.260 |
Why?
|
| Wounds and Injuries | 11 | 2024 | 246 | 1.250 |
Why?
|
| Uganda | 17 | 2025 | 56 | 1.210 |
Why?
|
| Tanzania | 14 | 2025 | 37 | 1.190 |
Why?
|
| Genome, Viral | 3 | 2025 | 136 | 1.140 |
Why?
|
| MicroRNAs | 5 | 2023 | 687 | 1.060 |
Why?
|
| Afghan Campaign 2001- | 13 | 2017 | 70 | 1.050 |
Why?
|
| Pyrimethamine | 11 | 2025 | 20 | 0.960 |
Why?
|
| Genotype | 17 | 2025 | 663 | 0.950 |
Why?
|
| Sulfadoxine | 9 | 2024 | 15 | 0.940 |
Why?
|
| Translocation, Genetic | 2 | 2024 | 71 | 0.930 |
Why?
|
| Nanopores | 1 | 2025 | 12 | 0.930 |
Why?
|
| Child | 31 | 2025 | 4526 | 0.910 |
Why?
|
| Viral Matrix Proteins | 1 | 2025 | 50 | 0.900 |
Why?
|
| Democratic Republic of the Congo | 11 | 2025 | 19 | 0.890 |
Why?
|
| Traumatology | 6 | 2024 | 15 | 0.870 |
Why?
|
| Prevalence | 18 | 2025 | 1380 | 0.870 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2025 | 491 | 0.850 |
Why?
|
| Air Ambulances | 5 | 2016 | 31 | 0.840 |
Why?
|
| Plasmodium vivax | 6 | 2024 | 46 | 0.840 |
Why?
|
| Malaria, Vivax | 6 | 2024 | 48 | 0.820 |
Why?
|
| Child, Preschool | 22 | 2025 | 1990 | 0.790 |
Why?
|
| Parasites | 4 | 2023 | 16 | 0.750 |
Why?
|
| RNA, Viral | 3 | 2021 | 276 | 0.730 |
Why?
|
| Haplotypes | 13 | 2022 | 131 | 0.720 |
Why?
|
| Drug Combinations | 12 | 2024 | 165 | 0.700 |
Why?
|
| Kenya | 11 | 2023 | 92 | 0.700 |
Why?
|
| Injury Severity Score | 7 | 2017 | 107 | 0.700 |
Why?
|
| Genomics | 8 | 2024 | 370 | 0.680 |
Why?
|
| Evolution, Molecular | 6 | 2021 | 322 | 0.630 |
Why?
|
| Warfare | 7 | 2018 | 41 | 0.620 |
Why?
|
| Infant | 18 | 2025 | 1645 | 0.610 |
Why?
|
| RNA, Messenger | 4 | 2022 | 1537 | 0.610 |
Why?
|
| DNA, Protozoan | 8 | 2025 | 50 | 0.600 |
Why?
|
| Primates | 4 | 2014 | 51 | 0.590 |
Why?
|
| Gene Expression Profiling | 4 | 2023 | 770 | 0.590 |
Why?
|
| Folic Acid Antagonists | 3 | 2024 | 8 | 0.580 |
Why?
|
| Antigenic Variation | 1 | 2017 | 7 | 0.560 |
Why?
|
| Gene Frequency | 6 | 2025 | 123 | 0.560 |
Why?
|
| Female | 48 | 2025 | 32878 | 0.550 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 193 | 0.530 |
Why?
|
| Male | 44 | 2025 | 29889 | 0.530 |
Why?
|
| Transportation of Patients | 3 | 2013 | 47 | 0.520 |
Why?
|
| Genotyping Techniques | 3 | 2025 | 21 | 0.520 |
Why?
|
| Plasmodium ovale | 3 | 2025 | 7 | 0.500 |
Why?
|
| Software | 2 | 2018 | 389 | 0.490 |
Why?
|
| Genome, Protozoan | 5 | 2024 | 13 | 0.490 |
Why?
|
| Zambia | 6 | 2025 | 17 | 0.480 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 525 | 0.450 |
Why?
|
| Gene Duplication | 3 | 2006 | 34 | 0.450 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2013 | 182 | 0.450 |
Why?
|
| Parasitic Sensitivity Tests | 5 | 2025 | 15 | 0.440 |
Why?
|
| Adult | 31 | 2025 | 16823 | 0.440 |
Why?
|
| Adolescent | 20 | 2025 | 6245 | 0.440 |
Why?
|
| Critical Care | 3 | 2018 | 396 | 0.430 |
Why?
|
| Chloroquine | 7 | 2025 | 61 | 0.430 |
Why?
|
| Trauma Centers | 4 | 2022 | 123 | 0.420 |
Why?
|
| Diagnostic Tests, Routine | 4 | 2024 | 50 | 0.420 |
Why?
|
| Asymptomatic Infections | 5 | 2025 | 29 | 0.420 |
Why?
|
| Bayes Theorem | 2 | 2025 | 122 | 0.420 |
Why?
|
| Laparoscopy | 1 | 2018 | 492 | 0.420 |
Why?
|
| Coinfection | 3 | 2024 | 58 | 0.410 |
Why?
|
| Rwanda | 4 | 2025 | 16 | 0.400 |
Why?
|
| Phylogeny | 9 | 2024 | 376 | 0.400 |
Why?
|
| Cervix Uteri | 2 | 2025 | 60 | 0.400 |
Why?
|
| HIV-1 | 3 | 2025 | 721 | 0.390 |
Why?
|
| Plasmodium malariae | 4 | 2024 | 5 | 0.390 |
Why?
|
| Membrane Proteins | 1 | 2017 | 895 | 0.370 |
Why?
|
| United States | 22 | 2024 | 7842 | 0.370 |
Why?
|
| Sarcoma, Kaposi | 2 | 2023 | 17 | 0.370 |
Why?
|
| Young Adult | 19 | 2025 | 4694 | 0.370 |
Why?
|
| Blood Component Removal | 3 | 2016 | 16 | 0.360 |
Why?
|
| Prognosis | 3 | 2025 | 1748 | 0.360 |
Why?
|
| Communicable Diseases | 2 | 2022 | 90 | 0.340 |
Why?
|
| Gene Deletion | 4 | 2024 | 309 | 0.340 |
Why?
|
| Cross-Sectional Studies | 12 | 2025 | 2575 | 0.340 |
Why?
|
| Incidence | 5 | 2023 | 1377 | 0.330 |
Why?
|
| Polymorphism, Genetic | 4 | 2024 | 191 | 0.330 |
Why?
|
| Iraq War, 2003-2011 | 6 | 2016 | 66 | 0.320 |
Why?
|
| Hypocalcemia | 3 | 2018 | 19 | 0.310 |
Why?
|
| Vaccination | 3 | 2023 | 362 | 0.310 |
Why?
|
| Parasitemia | 3 | 2024 | 47 | 0.310 |
Why?
|
| Ethiopia | 3 | 2023 | 8 | 0.300 |
Why?
|
| Amodiaquine | 2 | 2025 | 2 | 0.290 |
Why?
|
| Hospitals, Military | 3 | 2018 | 4 | 0.280 |
Why?
|
| Plasma Exchange | 2 | 2018 | 23 | 0.270 |
Why?
|
| Population Surveillance | 3 | 2018 | 206 | 0.270 |
Why?
|
| Endemic Diseases | 4 | 2024 | 23 | 0.270 |
Why?
|
| Malawi | 5 | 2022 | 11 | 0.260 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 435 | 0.260 |
Why?
|
| Genome | 3 | 2023 | 276 | 0.260 |
Why?
|
| Rh-Hr Blood-Group System | 2 | 2018 | 2 | 0.260 |
Why?
|
| Phenotype | 4 | 2025 | 1207 | 0.260 |
Why?
|
| Computational Biology | 2 | 2019 | 356 | 0.250 |
Why?
|
| Plateletpheresis | 2 | 2017 | 6 | 0.250 |
Why?
|
| Merozoite Surface Protein 1 | 4 | 2024 | 24 | 0.250 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2006 | 38 | 0.250 |
Why?
|
| Culicidae | 2 | 2023 | 12 | 0.240 |
Why?
|
| HIV Infections | 2 | 2025 | 969 | 0.240 |
Why?
|
| Membrane Transport Proteins | 3 | 2025 | 135 | 0.240 |
Why?
|
| War-Related Injuries | 2 | 2016 | 3 | 0.240 |
Why?
|
| Transcriptome | 2 | 2021 | 387 | 0.240 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2025 | 3 | 0.240 |
Why?
|
| Dried Blood Spot Testing | 1 | 2025 | 4 | 0.240 |
Why?
|
| Asia, Southeastern | 1 | 2025 | 6 | 0.230 |
Why?
|
| Disease Eradication | 1 | 2025 | 6 | 0.230 |
Why?
|
| Calcium | 3 | 2018 | 575 | 0.230 |
Why?
|
| Microsatellite Repeats | 3 | 2024 | 41 | 0.230 |
Why?
|
| Alleles | 4 | 2023 | 448 | 0.230 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2025 | 93 | 0.230 |
Why?
|
| Segmental Duplications, Genomic | 1 | 2024 | 2 | 0.230 |
Why?
|
| Molecular Probes | 2 | 2024 | 31 | 0.230 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2025 | 56 | 0.220 |
Why?
|
| Leukocytes | 1 | 2025 | 103 | 0.220 |
Why?
|
| Mining | 1 | 2024 | 4 | 0.220 |
Why?
|
| Urban Population | 1 | 2025 | 193 | 0.220 |
Why?
|
| Drug Resistance, Multiple | 1 | 2024 | 32 | 0.220 |
Why?
|
| Blood Group Antigens | 1 | 2024 | 7 | 0.220 |
Why?
|
| Sequence Analysis, DNA | 7 | 2025 | 415 | 0.210 |
Why?
|
| Polysaccharides | 1 | 2025 | 144 | 0.210 |
Why?
|
| Animals | 19 | 2023 | 20663 | 0.210 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 1469 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 44 | 0.210 |
Why?
|
| Afghanistan | 2 | 2013 | 14 | 0.210 |
Why?
|
| Antibody Formation | 1 | 2023 | 114 | 0.200 |
Why?
|
| Herpesvirus 8, Human | 1 | 2023 | 17 | 0.200 |
Why?
|
| Blood Transfusion | 3 | 2022 | 162 | 0.200 |
Why?
|
| Cambodia | 6 | 2021 | 27 | 0.200 |
Why?
|
| Mosquito Vectors | 1 | 2022 | 13 | 0.200 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 4 | 2024 | 22 | 0.200 |
Why?
|
| Cluster Analysis | 3 | 2018 | 265 | 0.190 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 31 | 0.190 |
Why?
|
| Vaccines | 1 | 2024 | 97 | 0.190 |
Why?
|
| Deer | 1 | 2022 | 12 | 0.190 |
Why?
|
| Host-Pathogen Interactions | 2 | 2023 | 262 | 0.190 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 242 | 0.190 |
Why?
|
| Insecticides | 1 | 2022 | 44 | 0.190 |
Why?
|
| Chagas Disease | 1 | 2022 | 36 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 54 | 0.190 |
Why?
|
| Trypanosoma cruzi | 1 | 2022 | 52 | 0.190 |
Why?
|
| Viral Proteins | 2 | 2021 | 263 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2001 | 11 | 0.190 |
Why?
|
| Mosaicism | 1 | 2001 | 30 | 0.180 |
Why?
|
| Ghana | 4 | 2022 | 14 | 0.180 |
Why?
|
| Receptors, KIR | 1 | 2021 | 4 | 0.180 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 507 | 0.180 |
Why?
|
| Anemia | 1 | 2022 | 127 | 0.180 |
Why?
|
| Aminoquinolines | 1 | 2021 | 16 | 0.180 |
Why?
|
| Naphthoquinones | 1 | 2021 | 6 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 422 | 0.180 |
Why?
|
| Mucous Membrane | 1 | 2021 | 22 | 0.170 |
Why?
|
| Biomedical Research | 1 | 2024 | 268 | 0.170 |
Why?
|
| Air Microbiology | 1 | 2021 | 11 | 0.170 |
Why?
|
| Premedication | 2 | 2018 | 20 | 0.170 |
Why?
|
| Pregnancy | 8 | 2022 | 2334 | 0.170 |
Why?
|
| Penis | 1 | 2021 | 33 | 0.170 |
Why?
|
| Air Pollution, Indoor | 1 | 2021 | 36 | 0.170 |
Why?
|
| Cohort Studies | 7 | 2023 | 2570 | 0.170 |
Why?
|
| Automobiles | 1 | 2021 | 66 | 0.170 |
Why?
|
| Transplant Recipients | 1 | 2020 | 35 | 0.170 |
Why?
|
| Herpesviridae Infections | 1 | 2020 | 27 | 0.170 |
Why?
|
| Herpesviridae | 1 | 2020 | 15 | 0.170 |
Why?
|
| Receptors, IgG | 1 | 2020 | 41 | 0.160 |
Why?
|
| Registries | 4 | 2018 | 888 | 0.160 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2019 | 48 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 724 | 0.160 |
Why?
|
| Quality Improvement | 4 | 2018 | 443 | 0.160 |
Why?
|
| Zimbabwe | 3 | 2025 | 3 | 0.160 |
Why?
|
| Survival Rate | 3 | 2017 | 851 | 0.160 |
Why?
|
| Crosses, Genetic | 1 | 2019 | 110 | 0.160 |
Why?
|
| Research Design | 1 | 2023 | 574 | 0.160 |
Why?
|
| Middle Aged | 11 | 2025 | 17612 | 0.160 |
Why?
|
| Time Factors | 6 | 2017 | 3768 | 0.160 |
Why?
|
| HLA-DR alpha-Chains | 1 | 2019 | 4 | 0.160 |
Why?
|
| HLA-DR3 Antigen | 1 | 2019 | 7 | 0.150 |
Why?
|
| Geography | 4 | 2021 | 37 | 0.150 |
Why?
|
| ROC Curve | 1 | 2019 | 282 | 0.150 |
Why?
|
| Leukapheresis | 2 | 2016 | 11 | 0.150 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 217 | 0.150 |
Why?
|
| Calcium Gluconate | 1 | 2018 | 6 | 0.150 |
Why?
|
| Health Policy | 2 | 2018 | 192 | 0.150 |
Why?
|
| Case-Control Studies | 5 | 2025 | 1119 | 0.150 |
Why?
|
| Emergency Treatment | 2 | 2016 | 57 | 0.150 |
Why?
|
| Benchmarking | 2 | 2023 | 136 | 0.150 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2018 | 30 | 0.140 |
Why?
|
| Fetal Blood | 1 | 2018 | 73 | 0.140 |
Why?
|
| Longitudinal Studies | 4 | 2023 | 1256 | 0.140 |
Why?
|
| Retrospective Studies | 10 | 2022 | 6658 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Erythrocyte Transfusion | 2 | 2017 | 75 | 0.140 |
Why?
|
| Mali | 1 | 2017 | 2 | 0.140 |
Why?
|
| Wounds, Gunshot | 1 | 2018 | 56 | 0.140 |
Why?
|
| Seroepidemiologic Studies | 3 | 2023 | 53 | 0.140 |
Why?
|
| Multidrug Resistance-Associated Proteins | 3 | 2025 | 17 | 0.140 |
Why?
|
| Peptide Library | 1 | 2018 | 37 | 0.140 |
Why?
|
| Tranexamic Acid | 1 | 2017 | 7 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 730 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 319 | 0.140 |
Why?
|
| Antifibrinolytic Agents | 1 | 2017 | 16 | 0.140 |
Why?
|
| DNA Copy Number Variations | 3 | 2024 | 71 | 0.140 |
Why?
|
| Endotoxins | 1 | 2018 | 81 | 0.140 |
Why?
|
| Molecular Sequence Data | 4 | 2015 | 1991 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2017 | 21 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 719 | 0.140 |
Why?
|
| Antipruritics | 1 | 2017 | 3 | 0.140 |
Why?
|
| Placenta Diseases | 1 | 2017 | 9 | 0.140 |
Why?
|
| Placenta | 1 | 2018 | 61 | 0.140 |
Why?
|
| Firearms | 1 | 2018 | 70 | 0.140 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 2680 | 0.140 |
Why?
|
| Infant, Low Birth Weight | 1 | 2017 | 60 | 0.130 |
Why?
|
| Mutation Rate | 1 | 2017 | 23 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 352 | 0.130 |
Why?
|
| Cholecalciferol | 1 | 2017 | 28 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2017 | 64 | 0.130 |
Why?
|
| Polyadenylation | 1 | 2017 | 51 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.130 |
Why?
|
| Violence | 1 | 2018 | 170 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2017 | 65 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Epitopes | 1 | 2018 | 290 | 0.130 |
Why?
|
| Spatial Analysis | 3 | 2023 | 12 | 0.130 |
Why?
|
| Loiasis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2017 | 71 | 0.130 |
Why?
|
| Babesia microti | 1 | 2016 | 7 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 206 | 0.130 |
Why?
|
| Babesiosis | 1 | 2016 | 12 | 0.130 |
Why?
|
| Head Injuries, Penetrating | 1 | 2016 | 5 | 0.130 |
Why?
|
| Tourniquets | 1 | 2016 | 6 | 0.130 |
Why?
|
| Groin | 1 | 2016 | 15 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 183 | 0.130 |
Why?
|
| Manikins | 1 | 2016 | 21 | 0.130 |
Why?
|
| Immunization, Passive | 3 | 2021 | 105 | 0.130 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2016 | 29 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2016 | 42 | 0.130 |
Why?
|
| Organizational Innovation | 2 | 2013 | 82 | 0.120 |
Why?
|
| Drug Monitoring | 2 | 2015 | 121 | 0.120 |
Why?
|
| Semen | 1 | 2016 | 48 | 0.120 |
Why?
|
| Blast Injuries | 1 | 2016 | 5 | 0.120 |
Why?
|
| Ebolavirus | 1 | 2016 | 39 | 0.120 |
Why?
|
| Microbiota | 1 | 2018 | 129 | 0.120 |
Why?
|
| Laparotomy | 1 | 2016 | 52 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 174 | 0.120 |
Why?
|
| Organizational Policy | 1 | 2016 | 52 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 158 | 0.120 |
Why?
|
| Mass Casualty Incidents | 2 | 2012 | 32 | 0.120 |
Why?
|
| Splenectomy | 1 | 2015 | 42 | 0.120 |
Why?
|
| Biota | 1 | 2015 | 3 | 0.120 |
Why?
|
| General Surgery | 1 | 2018 | 211 | 0.120 |
Why?
|
| Simulation Training | 1 | 2016 | 65 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2015 | 12 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2015 | 123 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2022 | 3293 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 671 | 0.120 |
Why?
|
| Rh Isoimmunization | 1 | 2014 | 1 | 0.120 |
Why?
|
| Sexual Behavior | 1 | 2016 | 194 | 0.110 |
Why?
|
| Ixodes | 1 | 2015 | 34 | 0.110 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2016 | 109 | 0.110 |
Why?
|
| Isoantibodies | 1 | 2014 | 35 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2016 | 196 | 0.110 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 74 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 149 | 0.110 |
Why?
|
| Piperazines | 2 | 2025 | 81 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 115 | 0.110 |
Why?
|
| Sirolimus | 1 | 2015 | 93 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2016 | 267 | 0.110 |
Why?
|
| Africa | 2 | 2024 | 27 | 0.110 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2016 | 98 | 0.110 |
Why?
|
| Phylogeography | 1 | 2014 | 6 | 0.110 |
Why?
|
| Analgesics | 1 | 2015 | 102 | 0.110 |
Why?
|
| RNA Interference | 1 | 2017 | 618 | 0.110 |
Why?
|
| Erythrocytes | 1 | 2015 | 149 | 0.110 |
Why?
|
| Biomarkers | 2 | 2024 | 1408 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 621 | 0.110 |
Why?
|
| Counseling | 1 | 2016 | 362 | 0.110 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 94 | 0.100 |
Why?
|
| Sickle Cell Trait | 1 | 2013 | 8 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2014 | 160 | 0.100 |
Why?
|
| Regional Medical Programs | 1 | 2012 | 7 | 0.100 |
Why?
|
| Blood Component Transfusion | 1 | 2012 | 11 | 0.100 |
Why?
|
| Arm Injuries | 1 | 2012 | 12 | 0.100 |
Why?
|
| Leg Injuries | 1 | 2012 | 16 | 0.100 |
Why?
|
| Mobile Health Units | 1 | 2012 | 11 | 0.100 |
Why?
|
| Africa, Central | 2 | 2022 | 3 | 0.100 |
Why?
|
| Mosquito Control | 2 | 2022 | 8 | 0.100 |
Why?
|
| Compartment Syndromes | 1 | 2012 | 13 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2014 | 321 | 0.100 |
Why?
|
| Pain Management | 1 | 2015 | 161 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 378 | 0.100 |
Why?
|
| Risk | 3 | 2021 | 377 | 0.100 |
Why?
|
| Models, Biological | 1 | 2017 | 1180 | 0.100 |
Why?
|
| Bacteria | 1 | 2015 | 306 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2025 | 1358 | 0.090 |
Why?
|
| Mefloquine | 2 | 2025 | 4 | 0.090 |
Why?
|
| Introns | 3 | 2019 | 111 | 0.090 |
Why?
|
| Resuscitation | 1 | 2012 | 72 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 222 | 0.090 |
Why?
|
| Quinolines | 2 | 2025 | 45 | 0.090 |
Why?
|
| Proguanil | 2 | 2022 | 6 | 0.090 |
Why?
|
| Risk Factors | 4 | 2025 | 5353 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 676 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 462 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 266 | 0.090 |
Why?
|
| Aged | 6 | 2025 | 14446 | 0.090 |
Why?
|
| Africa South of the Sahara | 2 | 2024 | 21 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 311 | 0.080 |
Why?
|
| Travel | 2 | 2021 | 42 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2023 | 207 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 327 | 0.080 |
Why?
|
| Principal Component Analysis | 2 | 2020 | 61 | 0.080 |
Why?
|
| Cytochromes b | 2 | 2021 | 4 | 0.080 |
Why?
|
| Atovaquone | 2 | 2021 | 5 | 0.080 |
Why?
|
| Blood Donors | 2 | 2020 | 23 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2020 | 2079 | 0.080 |
Why?
|
| Species Specificity | 2 | 2016 | 334 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2021 | 5680 | 0.070 |
Why?
|
| Citric Acid | 2 | 2018 | 20 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2017 | 3035 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 2005 | 299 | 0.070 |
Why?
|
| Viral Load | 2 | 2021 | 231 | 0.070 |
Why?
|
| Quinine | 1 | 2025 | 4 | 0.060 |
Why?
|
| History, 21st Century | 2 | 2017 | 172 | 0.060 |
Why?
|
| Cities | 1 | 2025 | 30 | 0.060 |
Why?
|
| Centromere | 2 | 2004 | 41 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 878 | 0.060 |
Why?
|
| Peru | 1 | 2024 | 14 | 0.060 |
Why?
|
| Exons | 2 | 2005 | 199 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2025 | 120 | 0.060 |
Why?
|
| Metagenomics | 1 | 2024 | 28 | 0.060 |
Why?
|
| South Sudan | 1 | 2024 | 1 | 0.060 |
Why?
|
| Ethanolamines | 1 | 2024 | 18 | 0.060 |
Why?
|
| Dihydropteroate Synthase | 1 | 2024 | 6 | 0.060 |
Why?
|
| Rats, Inbred BN | 1 | 2004 | 26 | 0.050 |
Why?
|
| Burkina Faso | 1 | 2024 | 2 | 0.050 |
Why?
|
| Health Surveys | 1 | 2025 | 313 | 0.050 |
Why?
|
| Health Facilities | 1 | 2024 | 43 | 0.050 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2023 | 6 | 0.050 |
Why?
|
| Recurrence | 2 | 2016 | 641 | 0.050 |
Why?
|
| Refugees | 1 | 2024 | 70 | 0.050 |
Why?
|
| Microdissection | 1 | 2023 | 7 | 0.050 |
Why?
|
| Ligases | 1 | 2023 | 28 | 0.050 |
Why?
|
| Formaldehyde | 1 | 2023 | 31 | 0.050 |
Why?
|
| Informatics | 1 | 2023 | 11 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2023 | 36 | 0.050 |
Why?
|
| Gabon | 1 | 2022 | 1 | 0.050 |
Why?
|
| Ethylenediamines | 1 | 2022 | 2 | 0.050 |
Why?
|
| Asparagine | 1 | 2022 | 25 | 0.050 |
Why?
|
| Quality Control | 2 | 2012 | 74 | 0.050 |
Why?
|
| Forests | 1 | 2022 | 7 | 0.050 |
Why?
|
| Rituximab | 1 | 2023 | 87 | 0.050 |
Why?
|
| Animals, Domestic | 1 | 2022 | 15 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2023 | 101 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 55 | 0.050 |
Why?
|
| Cats | 1 | 2022 | 87 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 126 | 0.050 |
Why?
|
| Genes, Duplicate | 1 | 2001 | 2 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2001 | 17 | 0.050 |
Why?
|
| Virus Replication | 1 | 2023 | 321 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 113 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2023 | 454 | 0.050 |
Why?
|
| Gene Dosage | 1 | 2001 | 65 | 0.050 |
Why?
|
| Cattle | 1 | 2022 | 310 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 208 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2012 | 583 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 168 | 0.040 |
Why?
|
| Base Sequence | 2 | 2014 | 1331 | 0.040 |
Why?
|
| Dogs | 1 | 2022 | 325 | 0.040 |
Why?
|
| Genome, Human | 1 | 2003 | 237 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 459 | 0.040 |
Why?
|
| Hydrodynamics | 1 | 2021 | 37 | 0.040 |
Why?
|
| Aerosols | 1 | 2021 | 47 | 0.040 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2020 | 10 | 0.040 |
Why?
|
| Pressure | 1 | 2021 | 79 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2022 | 187 | 0.040 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2020 | 19 | 0.040 |
Why?
|
| Investigational New Drug Application | 1 | 2020 | 1 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 1617 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2023 | 390 | 0.040 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2020 | 6 | 0.040 |
Why?
|
| Geographic Information Systems | 1 | 2020 | 23 | 0.040 |
Why?
|
| CD56 Antigen | 1 | 2020 | 17 | 0.040 |
Why?
|
| Protein Binding | 2 | 2016 | 1603 | 0.040 |
Why?
|
| Islands | 1 | 2020 | 2 | 0.040 |
Why?
|
| Haploidy | 1 | 2020 | 11 | 0.040 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2019 | 6 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 1147 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2019 | 13 | 0.040 |
Why?
|
| Genes, Protozoan | 1 | 2019 | 14 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 114 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 89 | 0.040 |
Why?
|
| Anopheles | 1 | 2019 | 21 | 0.040 |
Why?
|
| Environment | 1 | 2020 | 123 | 0.040 |
Why?
|
| Mice | 3 | 2023 | 10844 | 0.040 |
Why?
|
| Gene Library | 1 | 2020 | 102 | 0.040 |
Why?
|
| Demography | 1 | 2020 | 173 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2020 | 232 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2021 | 255 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 837 | 0.040 |
Why?
|
| Homozygote | 1 | 2019 | 124 | 0.040 |
Why?
|
| Chicago | 1 | 2018 | 27 | 0.040 |
Why?
|
| Mutagenesis | 2 | 2013 | 133 | 0.040 |
Why?
|
| Cultural Characteristics | 1 | 2018 | 37 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2019 | 95 | 0.040 |
Why?
|
| Peptides | 1 | 2022 | 574 | 0.040 |
Why?
|
| Philippines | 1 | 2018 | 7 | 0.040 |
Why?
|
| Schistosomiasis | 1 | 2018 | 5 | 0.040 |
Why?
|
| Bacterial Translocation | 1 | 2018 | 11 | 0.040 |
Why?
|
| Social Isolation | 1 | 2018 | 36 | 0.040 |
Why?
|
| Hookworm Infections | 1 | 2018 | 11 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 2018 | 18 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2022 | 361 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 359 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2018 | 49 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 768 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2020 | 664 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 477 | 0.040 |
Why?
|
| Peptidomimetics | 1 | 2018 | 6 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 145 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 173 | 0.040 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2018 | 7 | 0.040 |
Why?
|
| Surgeons | 1 | 2021 | 183 | 0.040 |
Why?
|
| Filgrastim | 1 | 2017 | 8 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2017 | 15 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 572 | 0.030 |
Why?
|
| Benin | 1 | 2017 | 2 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2020 | 255 | 0.030 |
Why?
|
| Gestational Age | 1 | 2018 | 189 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 2017 | 8 | 0.030 |
Why?
|
| Health Resources | 1 | 2018 | 95 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 127 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 49 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 753 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 201 | 0.030 |
Why?
|
| Liberia | 1 | 2016 | 11 | 0.030 |
Why?
|
| International Cooperation | 1 | 2017 | 90 | 0.030 |
Why?
|
| Carrier State | 1 | 2016 | 18 | 0.030 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2016 | 28 | 0.030 |
Why?
|
| Cameroon | 1 | 2016 | 2 | 0.030 |
Why?
|
| Microfilariae | 1 | 2016 | 4 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 130 | 0.030 |
Why?
|
| Condoms | 1 | 2016 | 48 | 0.030 |
Why?
|
| Zoonoses | 1 | 2016 | 9 | 0.030 |
Why?
|
| Serum Albumin, Human | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2040 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 2016 | 16 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 1 | 2016 | 24 | 0.030 |
Why?
|
| Azithromycin | 1 | 2016 | 32 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 840 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2016 | 43 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1558 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2016 | 115 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2016 | 67 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 2187 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 240 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2015 | 32 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 314 | 0.030 |
Why?
|
| Mental Health | 1 | 2018 | 371 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 112 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 467 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 99 | 0.030 |
Why?
|
| Live Birth | 1 | 2015 | 21 | 0.030 |
Why?
|
| Pulmonary Ventilation | 1 | 2015 | 38 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2013 | 1149 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 171 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 115 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2015 | 88 | 0.030 |
Why?
|
| Liver Failure | 1 | 2015 | 18 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2017 | 235 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1276 | 0.030 |
Why?
|
| Morphine | 1 | 2015 | 59 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2014 | 32 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 124 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 284 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 509 | 0.030 |
Why?
|
| Occupational Injuries | 1 | 2015 | 36 | 0.030 |
Why?
|
| Ketamine | 1 | 2015 | 38 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 443 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 124 | 0.030 |
Why?
|
| Biostatistics | 1 | 2014 | 5 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 772 | 0.030 |
Why?
|
| Fentanyl | 1 | 2015 | 76 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 935 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 69 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2015 | 101 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 173 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2015 | 267 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 113 | 0.030 |
Why?
|
| Korean War | 1 | 2013 | 1 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2014 | 173 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2018 | 707 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 1654 | 0.030 |
Why?
|
| Vietnam Conflict | 1 | 2013 | 26 | 0.030 |
Why?
|
| Retroelements | 2 | 2004 | 44 | 0.030 |
Why?
|
| Hospitals | 1 | 2016 | 393 | 0.030 |
Why?
|
| DNA Primers | 1 | 2013 | 293 | 0.020 |
Why?
|
| Shock, Hemorrhagic | 1 | 2012 | 20 | 0.020 |
Why?
|
| Forecasting | 1 | 2013 | 232 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 512 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 448 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 978 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2013 | 231 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 85 | 0.020 |
Why?
|
| Professional Competence | 1 | 2012 | 93 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 517 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 418 | 0.020 |
Why?
|
| Binding Sites | 1 | 2014 | 905 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 877 | 0.020 |
Why?
|
| Triage | 1 | 2012 | 126 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 487 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 779 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 1592 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 873 | 0.020 |
Why?
|
| Curriculum | 1 | 2012 | 599 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 1308 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2005 | 81 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 5462 | 0.010 |
Why?
|
| Base Composition | 1 | 2004 | 30 | 0.010 |
Why?
|
| RNA Splice Sites | 1 | 2004 | 23 | 0.010 |
Why?
|
| Chromosomes, Mammalian | 1 | 2004 | 34 | 0.010 |
Why?
|
| Telomere | 1 | 2004 | 52 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 2004 | 87 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2004 | 101 | 0.010 |
Why?
|
| Lemur | 1 | 2003 | 1 | 0.010 |
Why?
|
| Pongo pygmaeus | 1 | 2003 | 2 | 0.010 |
Why?
|
| RNA, Untranslated | 1 | 2004 | 103 | 0.010 |
Why?
|
| Papio | 1 | 2003 | 14 | 0.010 |
Why?
|
| DNA Transposable Elements | 1 | 2004 | 140 | 0.010 |
Why?
|
| CpG Islands | 1 | 2004 | 216 | 0.010 |
Why?
|
| Point Mutation | 1 | 2003 | 166 | 0.010 |
Why?
|
| Internet | 1 | 2005 | 469 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1980 | 0.010 |
Why?
|